- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Medtronic sees hit to revenue as hospitals delay elective procedures
United States - Medtronic Plc said on Tuesday its revenues across the world had plunged in recent weeks, as hospitals put off elective procedures that use its medical devices in order to save capacity to treat COVID-19 patients.
Weekly revenue from the United States declined about 60%, excluding bulk purchases, over the last few weeks, as hospitals focused their efforts on treating surging numbers of patients infected with the novel coronavirus, the world's largest standalone medical device maker said.
Read Also: 2 Italian biotech companies target to put COVID-19 vaccine in human trials in September 2020
Weekly revenue from China, where the pandemic started, has declined 20% to 40% since March 9, adding to the dent it expects to its overall fourth-quarter sales.
More than 2.5 million people globally have been reported to be infected by the virus and over 170,000 have died.
The company said it was running many of its factories at or near full capacity to have adequate stocks to support an anticipated rebound in procedures and was still on pace to ramp up production of much-needed ventilators by nearly five-fold to more than 1,000 per week by June-end.
Medtronic said it was in a strong position in terms of liquidity, with about $11 billion in cash and investments as of the most recent quarter, and an undrawn $3.5 billion credit facility.
Read Also: FDA approves generic version of Albuterol inhaler in view of Covid 19 pandemic
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.